{
  "trial_type": "IPCase",
  "date": {
    "era": "Heisei",
    "year": 23,
    "month": 6,
    "day": 14
  },
  "case_number": "平成22(行ケ)10158",
  "case_name": "審決取消請求事件",
  "court_name": "知的財産高等裁判所",
  "right_type": "特許権",
  "lawsuit_type": "行政訴訟",
  "lawsuit_id": "81417",
  "detail_page_link": "https://www.courts.go.jp/app/hanrei_jp/detail7?id=81417",
  "full_pdf_link": "https://www.courts.go.jp/app/files/hanrei_jp/417/081417_hanrei.pdf",
  "contents": "()\n()\n()\n(ii)\n(1) ()\n(ii)\n(2)\n()\nmg/kg mg/kg   .\n(1)\n(2)\n(3)\n(1)\n(2)\n(1)\nmg/kg mg/kg\ncarboxymethyl  cellulose  sodium    ml/kg\n(i)ii\nmg/kg mg/kg\ncarboxymethyl cellulose sodium Sigma\nml/kg\nII\nβ\n(2)\nCorea et al,Valsartan, a new angiotensin   antagonist for the treatment of\nessential  hypertension:  A  comparative  study  of  the  efficacy  and  safety  against\namlodipine(\n)Clinical\nPharmacology   Therapeutics, Vol.60,\n(3)\nCorea  et  al.Clinical\nPharmacology TherapeuticsVol.60p.341-346\nfixed\nmg/kg mg/kg %\n()\nII\nII\nII\nObjective\nmg mg\n®\nperipheral\nedema\n(4)\n(1)\n(2)\n(1)\n(2)\n(3)\n(4)\n(1)\nfixed  combination\n(2)\nmg/kg\nmg/kg\nmg/kg mg/kg\nml/kg\nmg/kg/day\nmg/kg/day\nml/kg\nfixed\ncombinationsuspensions\n(3)\n(4)\n(5)\n(6)\nabstractTableIII\n(7)\n(1)\n()\n(2)\nvalsartan\nnifedipinemg/kg\nmg/kg\ncarboxymethyl cellulose sodium  -\nml/kg\nmg/kg mg/kg\nml/kg -\n(3)\n(i)\nii\nml\n(4)\n()\n(5)\n-\nkg mg mg\n(4)\n-\nkg mg\nkg mg\n(6)\n(\n"
}